|Bid||5.80 x 900|
|Ask||6.15 x 800|
|Day's Range||5.80 - 6.41|
|52 Week Range||5.80 - 17.88|
|Beta (3Y Monthly)||1.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.14|
Five Prime Therapeutics Inc NASDAQ/NGS:FPRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for FPRX with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding FPRX is favorable, with net inflows of $2.47 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the departure of Dr. Sheila Gujrathi from the company’s board of directors. Dr. Gujrathi has served as a board member of Five Prime since December 2015 and is stepping down from the board to focus on her role as President and Chief Executive Officer of Gossamer Bio, Inc., a biopharmaceutical company that she co-founded in 2017 and that completed its initial public offering in February 2019.
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today ann
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today presented monotherapy data from the dose escalation portion of the Phase 1a/1b clinical trial of FPA150 in patients with advanced solid tumors. The data are the first presentation of FPA150 results and include safety and pharmacokinetics results from the Phase 1a monotherapy dose escalation portion of the study. The Phase 1a monotherapy portion of the study is being conducted in patients with advanced solid tumors, and the Phase 1b monotherapy expansion is enrolling patients with breast, ovarian and endometrial tumors that overexpress B7-H4.
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Carol Schafer to its Board of Directors. Ms. Schafer is an industry leader with more than 25 years of investment banking and equity capital markets experience in the biotechnology sector. “We welcome Carol to our board and look forward to her contributions as we continue to build Five Prime by advancing our differentiated clinical pipeline, leveraging our discovery platform, and collaborating with our strategic alliance partners,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics.
– Phase 1a/1b Study of First-in-class B7-H4 Antibody as Monotherapy in Patients with Advanced Solid Tumors –
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 4.67% and -6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.02. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced its results for the first quarter and provided an update on the company’s recent activities.
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Peninsula drug developer has four preclinical drugs aimed at triggering a process that it believes will kill cancer cells with genetic mutations.
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2019 financial results on Wednesday, May 8, 2019, after the U.S. financial markets close.
In December 2018, Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its latest earnings announcement, which showed company earnings became less negative compared to the previous year's level - gre...
How Genentech — with the help of a $1.7 billion merger — is breaking new ground in cancer … and more in our Health Care Digest.
Five Prime (FPRX) recently held a quarterly conference call and, importantly, all of the company's timelines remain on track; it has developed a broad pipeline with five drug candidates now in human clinical development, observes John McCamant, biotech expert and editor of The Medical Technology Stock Letter.